Lee, S.; Im, S.-A.; Kim, G.M.; Jung, K.H.; Kang, S.Y.; Park, I.H.; Kim, J.H.; Lee, K.E.; Ahn, H.K.; Lee, M.H.;
et al. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers 2020, 12, 3265.
https://doi.org/10.3390/cancers12113265
AMA Style
Lee S, Im S-A, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH,
et al. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers. 2020; 12(11):3265.
https://doi.org/10.3390/cancers12113265
Chicago/Turabian Style
Lee, Soohyeon, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee,
and et al. 2020. "Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)" Cancers 12, no. 11: 3265.
https://doi.org/10.3390/cancers12113265
APA Style
Lee, S., Im, S.-A., Kim, G. M., Jung, K. H., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., Lee, M. H., Kim, H.-J., Kim, H. J., Lee, J. I., Koh, S.-J., & Park, Y. H.
(2020). Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10). Cancers, 12(11), 3265.
https://doi.org/10.3390/cancers12113265
